Palus, Sandra

[["dc.bibliographiccitation.firstpage","19"],["dc.bibliographiccitation.journal","International Journal of Cardiology"],["dc.bibliographiccitation.lastpage","21"],["dc.bibliographiccitation.volume","238"],["dc.contributor.author","Palus, Sandra"],["dc.contributor.author","Springer, J. I."],["dc.contributor.author","Doehner, Wolfram"],["dc.contributor.author","von Haehling, Stephan"],["dc.contributor.author","Anker, Markus S."],["dc.contributor.author","Anker, Stefan-D."],["dc.date.accessioned","2018-11-07T10:22:26Z"],["dc.date.available","2018-11-07T10:22:26Z"],["dc.date.issued","2017"],["dc.description.abstract","Approximately 40-50% of the population over 80 years of age suffers from sarcopenia making this condition a major geriatric clinical disorder and a key challenge to healthy aging. The hallmark symptom of sarcopenia is the loss of muscle mass and strength without the loss of overall body weight. Sarcopenic patients are likely to have worse clinical outcomes and higher mortality compared to healthy individuals. This review will focus on animal models designed to study sarcopenia including hind-limb unloading, de-nervation, and immobilization by using casts or wire strategies, as well as using aged rodents. Currently there are no registered treatments for sarcopenia. Most sarcopenic individuals show signs of physical frailty, which leads to increases the prevalence of balance disorders, falls, fractures and pain. Therefore, is it essential to develop and use relevant animal models to further the research on sarcopenia therapy? (C) 2017 Elsevier B.V. All rights reserved."],["dc.identifier.doi","10.1016/j.ijcard.2017.03.152"],["dc.identifier.isi","000402478900004"],["dc.identifier.pmid","28465116"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42272"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Elsevier Ireland Ltd"],["dc.relation.issn","1874-1754"],["dc.relation.issn","0167-5273"],["dc.title","Models of sarcopenia: Short review"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Cachexia, Sarcopenia and Muscle"],["dc.bibliographiccitation.lastpage","10"],["dc.bibliographiccitation.volume","3"],["dc.contributor.author","Suzuki, Tsuyoshi"],["dc.contributor.author","Ebner, Nicole"],["dc.contributor.author","Palus, Sandra"],["dc.contributor.author","Haehling, Stephan von"],["dc.contributor.author","Springer, Jochen"],["dc.date.accessioned","2019-07-08T12:29:23Z"],["dc.date.accessioned","2021-10-27T13:21:17Z"],["dc.date.available","2019-07-08T12:29:23Z"],["dc.date.available","2021-10-27T13:21:17Z"],["dc.date.issued","2019"],["dc.description.abstract","Background: Medroxyprogesterone (MPA) and megestrol acetate (MA) are synthetic progesterone derivates. Progestagen is an approved drug for cancer cachexia in the USA and some Europe. These agents have been described to increase appetite and to lead to weight gain. However, the effects on survival are still unknown. The aim of this study was to evaluate the effects of progesterone on survival, cardiac function as well as appetite and body weight in the Yoshida hepatoma AH‐130 rat cancer cachexia model. Methods: In this study the effects of progesterone were tested in cachectic tumor bearing rats. Rats were treated with 0.5, 5 or 50mg/kg/d, respectively or placebo daily, starting one day after tumor inoculation for a period of 16 days. Cardiac function was analyzed by echocardiography at baseline and at day 11. Food intake was assessed before tumor inoculation and at day 11. Body weight and body composition were evaluated at the beginning and the end of study or day of euthanasia. Results: Survival was significantly improved by 5 mg/kg/d (HR: 0.48, 95%CI: 0.24‐0.95, p=0.0356). However, there was no significant difference between the progesterone treatment groups compared to placebo in body weight change and body composition, as well as food intake on day 11. Cardiac function also showed no significant difference compared to placebo. Conclusion: Progesterone improves survival, but has no beneficial effects on cardiac function, body weight and food intake in this aggressive hepatoma cancer cachexia rat model. Further studies are needed to elucidate the mechanism of the survival benefit."],["dc.description.sponsorship","Open Access-Publikationsfonds 2019"],["dc.identifier.doi","10.1002/rco2.11"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16258"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/92008"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Progesterone improves survival in hepatoma cachexia rat model"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","193"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of Cachexia Sarcopenia and Muscle"],["dc.bibliographiccitation.lastpage","198"],["dc.bibliographiccitation.volume","5"],["dc.contributor.author","Palus, Sandra"],["dc.contributor.author","von Haehling, Stephan"],["dc.contributor.author","Springer, Jochen"],["dc.date.accessioned","2018-11-07T09:35:56Z"],["dc.date.available","2018-11-07T09:35:56Z"],["dc.date.issued","2014"],["dc.description.abstract","The syndrome of cachexia, i.e., involuntary weight loss in patients with underlying diseases, sarcopenia, i.e., loss of muscle mass due to aging, and general muscle atrophy from disuse and/or prolonged bed rest have received more attention over the last decades. All lead to a higher morbidity and mortality in patients, and therefore, they represent a major socio-economic burden for the society today. This mini-review looks at recent developments in basic research that are relevant to the loss of skeletal muscle. It aims to cover the most significant publication of last 3 years on the causes and effects of muscle wasting, new targets for therapy development, and potential biomarkers for assessing skeletal muscle mass. The targets include the following: (1) E-3 ligases TRIM32, SOCS1, and SOCS3 by involving the elongin BC ubiquitin-ligase, Cbl-b, culling 7, Fbxo40, MG53 (TRIM72), and the mitochondrial Mul1; (2) the kinase MST1; and (3) the G-protein G alpha i(2). D(3)-creatine has the potential to be used as a novel biomarker that allows to monitor actual change in skeletal muscle mass over time. In conclusion, significant development efforts are being made by academic groups as well as numerous pharmaceutical companies to identify new target and biomarker muscles, as muscle wasting represents a great medical need, but no therapies have been approved in the last decades."],["dc.identifier.doi","10.1007/s13539-014-0157-7"],["dc.identifier.isi","000342061700005"],["dc.identifier.pmid","25163459"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12135"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32500"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Heidelberg"],["dc.relation.issn","2190-6009"],["dc.relation.issn","2190-5991"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Muscle wasting: an overview of recent developments in basic research"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","jcsm.13009"],["dc.bibliographiccitation.journal","Journal of Cachexia, Sarcopenia and Muscle"],["dc.contributor.author","Palus, Sandra"],["dc.contributor.author","Elkina, Yulia"],["dc.contributor.author","Braun, Tanja"],["dc.contributor.author","Haehling, Stephan"],["dc.contributor.author","Döhner, Wolfram"],["dc.contributor.author","Anker, Stefan D."],["dc.contributor.author","Cerami, Anthony"],["dc.contributor.author","Brines, Michael"],["dc.contributor.author","Springer, Jochen"],["dc.date.accessioned","2022-06-01T09:39:03Z"],["dc.date.available","2022-06-01T09:39:03Z"],["dc.date.issued","2022"],["dc.identifier.doi","10.1002/jcsm.13009"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/108378"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-572"],["dc.relation.eissn","2190-6009"],["dc.relation.issn","2190-5991"],["dc.title","The erythropoietin‐derived peptide ARA 284 reduces tissue wasting and improves survival in a rat model of cancer cachexia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","89"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","ESC Heart Failure"],["dc.bibliographiccitation.lastpage","97"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Musolino, Vincenzo"],["dc.contributor.author","Palus, Sandra"],["dc.contributor.author","Latouche, Celine"],["dc.contributor.author","Gliozzi, Micaela"],["dc.contributor.author","Bosco, Francesca"],["dc.contributor.author","Scarano, Federica"],["dc.contributor.author","Nucera, Saverio"],["dc.contributor.author","Carresi, Cristina"],["dc.contributor.author","Scicchitano, Miriam"],["dc.contributor.author","von Haehling, Stephan"],["dc.contributor.author","Jaisser, Frederic"],["dc.contributor.author","Hasenfuss, Gerd"],["dc.contributor.author","Anker, Stefan D."],["dc.contributor.author","Mollace, Vincenzo"],["dc.contributor.author","Springer, Jochen"],["dc.date.accessioned","2020-12-10T14:06:09Z"],["dc.date.available","2020-12-10T14:06:09Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1002/ehf2.v6.1"],["dc.identifier.issn","2055-5822"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/69800"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Cardiac expression of neutrophil gelatinase-associated lipocalin in a model of cancer cachexia-induced cardiomyopathy"],["dc.title.alternative","Cardiac expression of NGAL in cancer cachexia-induced cardiomyopathy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","594"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Journal of Cachexia, Sarcopenia and Muscle"],["dc.bibliographiccitation.lastpage","605"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Pötsch, Mareike S."],["dc.contributor.author","Ishida, Junichi"],["dc.contributor.author","Palus, Sandra"],["dc.contributor.author","Tschirner, Anika"],["dc.contributor.author","Haehling, Stephan"],["dc.contributor.author","Doehner, Wolfram"],["dc.contributor.author","Anker, Stefan D."],["dc.contributor.author","Springer, Jochen"],["dc.date.accessioned","2021-06-01T10:50:56Z"],["dc.date.available","2021-06-01T10:50:56Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1002/jcsm.12537"],["dc.identifier.eissn","2190-6009"],["dc.identifier.issn","2190-5991"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17186"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86832"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","2190-6009"],["dc.relation.issn","2190-5991"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","MT‐102 prevents tissue wasting and improves survival in a rat model of severe cancer cachexia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","45"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of cachexia, sarcopenia and muscle"],["dc.bibliographiccitation.lastpage","52"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Cvan Trobec, Katja"],["dc.contributor.author","Kerec Kos, Mojca"],["dc.contributor.author","Trontelj, Jurij"],["dc.contributor.author","Grabnar, Iztok"],["dc.contributor.author","Tschirner, Anika"],["dc.contributor.author","Palus, Sandra"],["dc.contributor.author","Anker, Stefan D."],["dc.contributor.author","Springer, Jochen"],["dc.contributor.author","Lainscak, Mitja"],["dc.date.accessioned","2019-07-09T11:42:33Z"],["dc.date.available","2019-07-09T11:42:33Z"],["dc.date.issued","2015-03-01"],["dc.description.abstract","BACKGROUND: Body wasting and cachexia change body composition and organ function, with effects on drug pharmacokinetics. The aim of this study was to investigate how cancer and cancer cachexia modify liver metabolism and renal drug elimination in rats. METHODS: Nine male Wistar-Han rats received a single oral dose of midazolam and propranolol (markers of hepatic metabolism), and 10 rats received single intravenous dose of iohexol, a marker of glomerular filtration rate. After drug delivery, multiple dried blood samples were obtained within 2 h post-dose to evaluate drug pharmacokinetic profiles. After baseline sampling (D0), rats were injected with tumour cells. Drug application and blood sampling were repeated when rats developed tumours (Day 5-D5), and when rats were severely cachectic (Day 10-D10). Clearance (CL) and volume of distribution (Vd) of drugs were assessed with non-linear mixed effects modelling. Weight and body composition were measured on D0 and D10 and were related to pharmacokinetic parameters. RESULTS: All three drugs showed non-significant trend towards increased CL and Vd on D5. On D10, midazolam and propranolol CL and midazolam Vd significantly decreased from baseline (-80.5%, -79.8%, and -72.0%, respectively, P < 0.05 for all). Iohexol CL decreased by 29.8% from baseline value on D10, which was related to body weight loss (Pearson's r = 0.837, P = 0.019). CONCLUSIONS: Hepatic metabolism and renal drug elimination are significantly reduced in cachexia, which could increase risk of dose-related adverse events."],["dc.identifier.doi","10.1002/jcsm.12012"],["dc.identifier.pmid","26136411"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13568"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58694"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2190-5991"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Influence of cancer cachexia on drug liver metabolism and renal elimination in rats."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","jcsm.13116"],["dc.bibliographiccitation.journal","Journal of Cachexia, Sarcopenia and Muscle"],["dc.contributor.author","Yuan, Luping"],["dc.contributor.author","Springer, Jochen"],["dc.contributor.author","Palus, Sandra"],["dc.contributor.author","Busquets, Silvia"],["dc.contributor.author","Jové, Queralt"],["dc.contributor.author","Alves de Lima Junior, Edson"],["dc.contributor.author","Anker, Markus S."],["dc.contributor.author","von Haehling, Stephan"],["dc.contributor.author","Álvarez Ladrón, Natalia"],["dc.contributor.author","Millman, Oliver"],["dc.contributor.author","Argiles, Josep M."],["dc.date.accessioned","2022-12-01T08:31:17Z"],["dc.date.available","2022-12-01T08:31:17Z"],["dc.date.issued","2022"],["dc.identifier.doi","10.1002/jcsm.13116"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/118130"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-621"],["dc.relation.eissn","2190-6009"],["dc.relation.issn","2190-5991"],["dc.title","The atypical β‐blocker S‐oxprenolol reduces cachexia and improves survival in a rat cancer cachexia model"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","640"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","International Journal of Cardiology"],["dc.bibliographiccitation.lastpage","644"],["dc.bibliographiccitation.volume","176"],["dc.contributor.author","Palus, Sandra"],["dc.contributor.author","von Haehling, Stephan"],["dc.contributor.author","Springer, Jochen"],["dc.date.accessioned","2018-11-07T09:33:30Z"],["dc.date.available","2018-11-07T09:33:30Z"],["dc.date.issued","2014"],["dc.description.abstract","The syndrome of cachexia, i.e, involuntary weight loss in patients with underlying diseases, sarcopenia, i.e, loss of muscle mass due to ageing, and general muscle atrophy from disuse and/or prolonged bed rest have received more attention over the last decades. All lead to a higher morbidity and mortality in patients and therefore, they represent a major socio-economic burden for the society today. This mini-review looks at recent developments in basic research that are relevant to the loss of skeletal muscle. It aims to cover the most significant publication of last three years on the causes and effects of muscle wasting, new targets for therapy development and potential biomarkers for assessing skeletal muscle mass. The targets include 1) E-3 ligases: TRIM32, SOCS1 and SOCS3 by involving the elongin BC ubiquitin-ligase, Cbl-b, culling 7, Fbx040, MG53 (TRIM72) and the mitochondrial Mull, 2) the kinase MST1 and 3) the G-protein G alpha i(2) D(3)-creatine has the potential to be used as a novel biomarker that allows to monitor actual change in skeletal muscle mass over time. In conclusion, significant development efforts are being made by academic groups as well as numerous pharmaceutical companies to identify new targets and biomarkers muscle, as muscle wasting represents a great medical need, but no therapies have been approved in the last decades. (C) 2014 Elsevier Ireland Ltd. All rights reserved."],["dc.identifier.doi","10.1016/j.ijcard.2014.08.086"],["dc.identifier.isi","000343893300037"],["dc.identifier.pmid","25205489"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/31979"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Ireland Ltd"],["dc.relation.issn","1874-1754"],["dc.relation.issn","0167-5273"],["dc.title","Muscle wasting: An overview of recent developments in basic research"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","377"],["dc.bibliographiccitation.journal","European Journal of Heart Failure"],["dc.bibliographiccitation.lastpage","378"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Konishi, Masaaki"],["dc.contributor.author","Drescher, C."],["dc.contributor.author","Pelgrim, Loes"],["dc.contributor.author","Tschirner, Anika"],["dc.contributor.author","Baumgarten, A."],["dc.contributor.author","von Haehling, S."],["dc.contributor.author","Palus, Sandra"],["dc.contributor.author","Doehner, Wolfram"],["dc.contributor.author","Anker, Stefan-D."],["dc.contributor.author","Springer, J. I."],["dc.date.accessioned","2018-11-07T09:57:28Z"],["dc.date.available","2018-11-07T09:57:28Z"],["dc.date.issued","2015"],["dc.identifier.isi","000366200403455"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37162"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.issn","1879-0844"],["dc.relation.issn","1388-9842"],["dc.title","Febuxostat reduces cancer cachexia-induced cardiomyopathy"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]